Simple SummaryAfter banning the use of antibiotics as growth promoters in poultry production, scientists had to find efficient and safe alternatives. Because of their useful properties, two types of probiotic bacteria were chosen to be administrated in a broiler diet, either individually or combined. Useful effects were obtained regarding improvements of growth performance, and immunity.AbstractA total of 120 1-day-old commercial Cobb chicks were used to study the effects of Clostridium butyricum (C. butyricum) and/or Saccharomyces cerevisiae (S. cerevisiae) on growth performance, intestinal health, and immune status in broilers. The experimental groups were as follows: G1; basal diet (BD), G2; basal diet (BD) plus C. butyricum preparation at 0.5 g/kg diet, G3; BD plus S. cerevisiae preparation at 0.5 g/kg diet, G4; BD plus 0.25 g/kg C. butyricum preparation plus 0.25 g/kg S. cerevisiae. Results showed that the total body weight gain, feed conversion efficiency, and protein efficiency ratio were significantly higher (p < 0.05) in the G4 group than in the other groups. The mortality percentage was reduced in the probiotic-supplemented groups. The villi height was elongated, and the villus height/crypt depth ratio was significantly increased in G2 and G4 chicks, compared to those in the control. The crypt depth was significantly decreased in all the probiotic-supplemented groups. Hemagglutination inhibition titers for Newcastle disease virus (NDV) were markedly increased in G2 and G4 chicks at 35 days of age, compared to those in G3 and control chicks. These results showed that dietary supplementation of a combined mixture of C. butyricum and S. cerevisiae in an equal ratio (G4) was more effective in improving growth performance, immune status, and gut health of broilers, compared with individual supplementation at a full dose.

In December 2019, the novel coronavirus disease pandemic (COVID-19) that began in China had infected more than 56 million individuals worldwide and accounted for more than 1.344.000 fatalities. With the dawn of this novel coronavirus (SARS-CoV-2), there was a requirement to select potential therapies that might effectively kill the virus, accelerate the recovery, or decrease the case fatality rate. Besides the currently available antiviral medications for HIV and HCV, the chloroquine/hydroxychloroquine (CQ/HCQ) regimen with or without azithromycin has been repurposed in China and was recommended by the National Health Commission, China in mid-February 2020. By this time, the selection of this regimen was based on its efficacy against the previous SARS-CoV-1 virus and its potential to inhibit viral replication of the SARS-CoV-2 in vitro. There was a shortage of robust clinical proof about the effectiveness of this regimen against the novel SARS-CoV-2. Therefore, extensive research effort has been made by several researchers worldwide to investigate whether this regimen is safe and effective for the management of COVID-19. This review article provides a comprehensive overview of the CQ/HCQ regimen. It summarizes the evaluating data from in vitro studies and clinical studies either for the protection or the treatment against SARS-CoV-2. There is a sharp difference of opinion about the role of CQ/HCQ regimen in treatment of COVID-19. The literature data are controversial and contradictory due to the diverse study design, population selection, dosage, regimen, and outcome measures. Current evidence from the two largest randomized-controlled trials (recovery and solidarity) suggests that the HCQ regimen does not decrease COVID-19 patients’ mortality. However, conflicting data were published from observational studies showing that the drug might be sufficient. Therefore, more investigations are needed to emphasize these findings.